Date lodged: 16 March 2017
To ask the Scottish Government what action it is taking to improve the (a) diagnosis and (b) treatment of Lynch syndrome.
Answered by: Aileen Campbell 29 March 2017
In Scotland, it is the responsibility of the Molecular Pathology Consortium (MPC) Steering Group to make overall decisions with regard to the availability of molecular pathology tests, such as genetic testing for Lynch syndrome. The current guidance from the MPC is to test anyone who has been diagnosed with colorectal cancer before the age of 60 - this was raised from under the age of 50 in 2015, to ensure more people than ever are now covered by the testing protocols. Where family testing is required, this is available through the Scottish Clinical Genetics service.
Patients may be given the opportunity to take part in the Cancer Prevention Project 3 (CaPP3). This project focuses on finding the right dose of aspirin for people with a mismatch repair gene defect, the underlying cause of Lynch syndrome, to prevent cancer from developing. Anyone who takes part in CaPP3 will be invited to be part of a national registry which can provide careful follow-up to report side effects and provide detailed information about any cancers or polyps which are found on routine check-ups.